普米克令舒联合特布他林雾化吸入治疗AECOPD的疗效  

Effect of Inhalation Therapy of Pulmicort in Joint with Terbutaline on AECOPD

作　　者：钱瑜琳 陈涛[1] 

机构地区：[1]上海市宝山区罗店医院呼吸科,上海201908

出　　处：《中国医药指南》2016年第10期9-10,共2页Guide of China Medicine

摘　　要：目的 探讨普米克令舒联合特布他林雾化吸入治疗慢性阻塞性肺疾病（AECOPD）的临床疗法。方法 符合AECOPD诊断标准共153例,按照就诊顺序随机区组分组分成两组,治疗组76例,对照组77例,两组均采用综合治疗（氧疗,抗生素,化痰喘定,平喘等）,治疗组在其基础上加用布地奈德4 mg,Bid,联合特布他林雾化5 mg,Bid,吸入治疗,对照组为常规治疗基础上,加用全身激素甲强龙40 mg静推,观察治疗7～10 d前后血气分析,临床症状变化和不良反应,肺功能。结果 治疗组和对照组临床症状、体征比较、治疗前后血气分析、临床疗效比较中均无统计学差异。结论 治疗组布地奈德联合特布他林雾化吸入治疗AECOPD可全面代替传统激素全身静脉注射,安全性高,不良反应少。Objeetive We aim to investigate clinical efficiency of Pulmicort combined with terbutaline inhalation to treat chronic obstructive pulmonary disease （AECOPD）. Method According to AECOPD diagnostic criteria,We finally select 153 cases. These cases are divided into two groups in order of treatment by randomized block. The treatment group has 76 cases while the control group has 77 cases. Both groups were combined therapy （oxygen, antibiotics, phlegm and asthma, asthma, etc.）. On the basis of the treatment,the treatment group combined budesonide 4 mg, twice a day, with the joint of terbutaline atomization 5 mg, inhalation treatment, twice a day. The control group on the basis of conventional therapy, use systemic corticosteroids plus methylprednisolone 40 mg, intravenous injection.We observe blood gas analysis, clinical symptoms and adverse changes in lung function before and after treatment in 7-10 days. Result We compare the treatment group withthe control group of clinical symptoms, signs comparison, blood gas analysis before and after treatment, clinical efficiency compatrison.There was no statistical difference in all these comparisons. Conclusion In the treatment of AECOPD, the treatment group, budesonide inhalation therapy combined with terbutaline can fully replace traditional hormone intravenous injection, with high safety, and less adverse reactions.

关 键 词：布地奈德 特布他林 雾化吸入 慢性阻塞性肺疾病 

分 类 号：R563.8[医药卫生—呼吸系统]